Ivacaftor, designated a CFTR potentiator (Van Goor et al., 2009), has been shown to increase activity of the G551D mutation in patients with CF, resulting in better lung function, improved quality of life, and increased time to exacerbation (Ramsey et al., 2011; Rowe et al., 2014). Here, CFTR is linked to cystic fibrosis.